Alar Pharmaceuticals Inc. (TPEX:6785)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
283.00
+11.00 (4.04%)
Oct 9, 2025, 1:30 PM CST
4.04%
Market Cap18.90B
Revenue (ttm)7.07M
Net Income (ttm)-17.49M
Shares Out66.80M
EPS (ttm)-0.27
PE Ration/a
Forward PEn/a
Dividend0.25 (0.09%)
Ex-Dividend DateJun 10, 2025
Volume232,169
Average Volume378,466
Open270.00
Previous Close272.00
Day's Range270.00 - 290.00
52-Week Range108.50 - 293.00
Beta0.15
RSI76.92
Earnings DateNov 7, 2025

About Alar Pharmaceuticals

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson’s disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan. [Read more]

Sector Healthcare
Founded 2016
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6785
Full Company Profile

Financial Performance

In 2024, Alar Pharmaceuticals's revenue was 5.82 million, a decrease of -98.76% compared to the previous year's 469.27 million. Earnings were 18.17 million, a decrease of -95.25%.

Financial Statements

News

There is no news available yet.